CN117427180A - 一种活性多肽或蛋白的聚乙二醇缀合物的制备方法 - Google Patents
一种活性多肽或蛋白的聚乙二醇缀合物的制备方法 Download PDFInfo
- Publication number
- CN117427180A CN117427180A CN202310902991.1A CN202310902991A CN117427180A CN 117427180 A CN117427180 A CN 117427180A CN 202310902991 A CN202310902991 A CN 202310902991A CN 117427180 A CN117427180 A CN 117427180A
- Authority
- CN
- China
- Prior art keywords
- concentration
- polyethylene glycol
- protein
- buffer
- reaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 55
- 229920001223 polyethylene glycol Polymers 0.000 title claims abstract description 54
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 54
- 239000002202 Polyethylene glycol Substances 0.000 title claims abstract description 52
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 46
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 46
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 44
- 238000002360 preparation method Methods 0.000 title abstract description 24
- 238000006243 chemical reaction Methods 0.000 claims abstract description 51
- 125000000524 functional group Chemical group 0.000 claims abstract description 14
- 238000002156 mixing Methods 0.000 claims abstract description 5
- 150000003839 salts Chemical class 0.000 claims description 51
- 108010092464 Urate Oxidase Proteins 0.000 claims description 32
- 239000007853 buffer solution Substances 0.000 claims description 25
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 20
- 239000000243 solution Substances 0.000 claims description 17
- 239000000872 buffer Substances 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 15
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims description 11
- 239000004327 boric acid Substances 0.000 claims description 11
- 239000011780 sodium chloride Substances 0.000 claims description 10
- 102000004190 Enzymes Human genes 0.000 claims description 8
- 108090000790 Enzymes Proteins 0.000 claims description 8
- 108010014251 Muramidase Proteins 0.000 claims description 8
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims description 8
- 229940088598 enzyme Drugs 0.000 claims description 8
- 239000004325 lysozyme Substances 0.000 claims description 8
- 235000010335 lysozyme Nutrition 0.000 claims description 8
- 229960000274 lysozyme Drugs 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 5
- 239000008363 phosphate buffer Substances 0.000 claims description 5
- 241000186074 Arthrobacter globiformis Species 0.000 claims description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 4
- 239000007983 Tris buffer Substances 0.000 claims description 3
- 244000005700 microbiome Species 0.000 claims description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 claims description 2
- 241000894006 Bacteria Species 0.000 claims description 2
- 239000007995 HEPES buffer Substances 0.000 claims description 2
- 239000008351 acetate buffer Substances 0.000 claims description 2
- 239000007979 citrate buffer Substances 0.000 claims description 2
- 239000002953 phosphate buffered saline Substances 0.000 claims description 2
- 102000016943 Muramidase Human genes 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 230000004048 modification Effects 0.000 abstract description 48
- 238000012986 modification Methods 0.000 abstract description 48
- 230000000694 effects Effects 0.000 abstract description 18
- 230000007423 decrease Effects 0.000 abstract description 8
- 230000006320 pegylation Effects 0.000 abstract description 5
- 239000012295 chemical reaction liquid Substances 0.000 abstract description 3
- 235000018102 proteins Nutrition 0.000 description 37
- 208000012839 conversion disease Diseases 0.000 description 11
- -1 O-substituted hydroxylamines Chemical class 0.000 description 10
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 8
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 8
- 150000001413 amino acids Chemical group 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- YIXJRHPUWRPCBB-UHFFFAOYSA-N magnesium nitrate Chemical compound [Mg+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O YIXJRHPUWRPCBB-UHFFFAOYSA-N 0.000 description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 8
- 102100033468 Lysozyme C Human genes 0.000 description 7
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 6
- 239000001095 magnesium carbonate Substances 0.000 description 6
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 6
- ZJIFDEVVTPEXDL-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) hydrogen carbonate Chemical compound OC(=O)ON1C(=O)CCC1=O ZJIFDEVVTPEXDL-UHFFFAOYSA-N 0.000 description 5
- AASBXERNXVFUEJ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) propanoate Chemical compound CCC(=O)ON1C(=O)CCC1=O AASBXERNXVFUEJ-UHFFFAOYSA-N 0.000 description 5
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 5
- 239000005695 Ammonium acetate Substances 0.000 description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
- 235000019257 ammonium acetate Nutrition 0.000 description 5
- 229940043376 ammonium acetate Drugs 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- OKXGHXHZNCJMSV-UHFFFAOYSA-N nitro phenyl carbonate Chemical compound [O-][N+](=O)OC(=O)OC1=CC=CC=C1 OKXGHXHZNCJMSV-UHFFFAOYSA-N 0.000 description 5
- 239000001103 potassium chloride Substances 0.000 description 5
- 235000011164 potassium chloride Nutrition 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 4
- 235000019270 ammonium chloride Nutrition 0.000 description 4
- 229910000019 calcium carbonate Inorganic materials 0.000 description 4
- ZCCIPPOKBCJFDN-UHFFFAOYSA-N calcium nitrate Chemical compound [Ca+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O ZCCIPPOKBCJFDN-UHFFFAOYSA-N 0.000 description 4
- 238000001962 electrophoresis Methods 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 239000004337 magnesium citrate Substances 0.000 description 4
- 229960005336 magnesium citrate Drugs 0.000 description 4
- 235000002538 magnesium citrate Nutrition 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 4
- 229910000160 potassium phosphate Inorganic materials 0.000 description 4
- 235000011009 potassium phosphates Nutrition 0.000 description 4
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 4
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical class O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 4
- 230000032258 transport Effects 0.000 description 4
- PLSARIKBYIPYPF-UHFFFAOYSA-H trimagnesium dicitrate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PLSARIKBYIPYPF-UHFFFAOYSA-H 0.000 description 4
- 241000186063 Arthrobacter Species 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 3
- 150000001299 aldehydes Chemical class 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 description 3
- 239000001639 calcium acetate Substances 0.000 description 3
- 235000011092 calcium acetate Nutrition 0.000 description 3
- 229960005147 calcium acetate Drugs 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 230000031700 light absorption Effects 0.000 description 3
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 3
- 239000011654 magnesium acetate Substances 0.000 description 3
- 235000011285 magnesium acetate Nutrition 0.000 description 3
- 229940069446 magnesium acetate Drugs 0.000 description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 description 3
- FKWSMBAMOQCVPV-UHFFFAOYSA-N magnesium dicyanide Chemical compound [Mg+2].N#[C-].N#[C-] FKWSMBAMOQCVPV-UHFFFAOYSA-N 0.000 description 3
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 description 3
- 239000004137 magnesium phosphate Substances 0.000 description 3
- 229960002261 magnesium phosphate Drugs 0.000 description 3
- 229910000157 magnesium phosphate Inorganic materials 0.000 description 3
- 235000010994 magnesium phosphates Nutrition 0.000 description 3
- 125000005439 maleimidyl group Chemical class C1(C=CC(N1*)=O)=O 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 description 3
- 229910052939 potassium sulfate Inorganic materials 0.000 description 3
- 235000011151 potassium sulphates Nutrition 0.000 description 3
- 239000012460 protein solution Substances 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- 229940116269 uric acid Drugs 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 239000001099 ammonium carbonate Substances 0.000 description 2
- 235000012501 ammonium carbonate Nutrition 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 229940053198 antiepileptics succinimide derivative Drugs 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 2
- 239000001354 calcium citrate Substances 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 125000000000 cycloalkoxy group Chemical group 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 2
- 238000003028 enzyme activity measurement method Methods 0.000 description 2
- 238000001952 enzyme assay Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 239000003607 modifier Substances 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 235000011056 potassium acetate Nutrition 0.000 description 2
- 239000001508 potassium citrate Substances 0.000 description 2
- 229960002635 potassium citrate Drugs 0.000 description 2
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 2
- 235000011082 potassium citrates Nutrition 0.000 description 2
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 2
- 239000004323 potassium nitrate Substances 0.000 description 2
- 235000010333 potassium nitrate Nutrition 0.000 description 2
- 239000008057 potassium phosphate buffer Substances 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 239000004317 sodium nitrate Substances 0.000 description 2
- 235000010344 sodium nitrate Nutrition 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 235000013337 tricalcium citrate Nutrition 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- DYMYLBQTHCJHOQ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) butanoate Chemical compound CCCC(=O)ON1C(=O)CCC1=O DYMYLBQTHCJHOQ-UHFFFAOYSA-N 0.000 description 1
- DRLIANXPAARUMI-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) pentanoate Chemical compound CCCCC(=O)ON1C(=O)CCC1=O DRLIANXPAARUMI-UHFFFAOYSA-N 0.000 description 1
- FHZSIZRTNHGLSX-FLMSMKGQSA-N (2s)-1-[(2s)-4-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-3-hydroxypropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-4-oxobutanoyl]pyrrolidine-2-carboxyl Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(N)=O)C(=O)N1[C@@H](CCC1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=CC=C1 FHZSIZRTNHGLSX-FLMSMKGQSA-N 0.000 description 1
- PAWQVTBBRAZDMG-UHFFFAOYSA-N 2-(3-bromo-2-fluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC(Br)=C1F PAWQVTBBRAZDMG-UHFFFAOYSA-N 0.000 description 1
- KXSKAZFMTGADIV-UHFFFAOYSA-N 2-[3-(2-hydroxyethoxy)propoxy]ethanol Chemical compound OCCOCCCOCCO KXSKAZFMTGADIV-UHFFFAOYSA-N 0.000 description 1
- HFDKKNHCYWNNNQ-YOGANYHLSA-N 75976-10-2 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)N)C(C)C)[C@@H](C)O)C1=CC=C(O)C=C1 HFDKKNHCYWNNNQ-YOGANYHLSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 239000004254 Ammonium phosphate Substances 0.000 description 1
- 102100022987 Angiogenin Human genes 0.000 description 1
- 102400000068 Angiostatin Human genes 0.000 description 1
- 108010079709 Angiostatins Proteins 0.000 description 1
- 101710095339 Apolipoprotein E Proteins 0.000 description 1
- 102100029470 Apolipoprotein E Human genes 0.000 description 1
- 102100033367 Appetite-regulating hormone Human genes 0.000 description 1
- 241000228197 Aspergillus flavus Species 0.000 description 1
- 101800001288 Atrial natriuretic factor Proteins 0.000 description 1
- 102400001282 Atrial natriuretic peptide Human genes 0.000 description 1
- 101800001890 Atrial natriuretic peptide Proteins 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 102100023995 Beta-nerve growth factor Human genes 0.000 description 1
- 101000645291 Bos taurus Metalloproteinase inhibitor 2 Proteins 0.000 description 1
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N Butyraldehyde Chemical group CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 108010074051 C-Reactive Protein Proteins 0.000 description 1
- 102100032752 C-reactive protein Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 102400000113 Calcitonin Human genes 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 102100025841 Cholecystokinin Human genes 0.000 description 1
- 101800001982 Cholecystokinin Proteins 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 102100023804 Coagulation factor VII Human genes 0.000 description 1
- 229940122097 Collagenase inhibitor Drugs 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
- 102000012289 Corticotropin-Releasing Hormone Human genes 0.000 description 1
- 108010022152 Corticotropin-Releasing Hormone Proteins 0.000 description 1
- 241000235646 Cyberlindnera jadinii Species 0.000 description 1
- 102000001189 Cyclic Peptides Human genes 0.000 description 1
- 108010069514 Cyclic Peptides Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical group OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 108010076282 Factor IX Proteins 0.000 description 1
- 108010023321 Factor VII Proteins 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 108010054265 Factor VIIa Proteins 0.000 description 1
- 108010071289 Factor XIII Proteins 0.000 description 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 description 1
- 108700012941 GNRH1 Proteins 0.000 description 1
- 102000004862 Gastrin releasing peptide Human genes 0.000 description 1
- 108090001053 Gastrin releasing peptide Proteins 0.000 description 1
- 102400000321 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 108010088406 Glucagon-Like Peptides Proteins 0.000 description 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 1
- 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 description 1
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 102000007625 Hirudins Human genes 0.000 description 1
- 108010007267 Hirudins Proteins 0.000 description 1
- 101000629400 Homo sapiens Mesoderm-specific transcript homolog protein Proteins 0.000 description 1
- 101000669513 Homo sapiens Metalloproteinase inhibitor 1 Proteins 0.000 description 1
- 101000604197 Homo sapiens Neuronatin Proteins 0.000 description 1
- 101000693243 Homo sapiens Paternally-expressed gene 3 protein Proteins 0.000 description 1
- 102000002265 Human Growth Hormone Human genes 0.000 description 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000001617 Interferon Receptors Human genes 0.000 description 1
- 108010054267 Interferon Receptors Proteins 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 1
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 1
- 102100026821 Mesoderm-specific transcript homolog protein Human genes 0.000 description 1
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108010056852 Myostatin Proteins 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102100038816 Neuronatin Human genes 0.000 description 1
- 108010053775 Nisin Proteins 0.000 description 1
- NVNLLIYOARQCIX-MSHCCFNRSA-N Nisin Chemical compound N1C(=O)[C@@H](CC(C)C)NC(=O)C(=C)NC(=O)[C@@H]([C@H](C)CC)NC(=O)[C@@H](NC(=O)C(=C/C)/NC(=O)[C@H](N)[C@H](C)CC)CSC[C@@H]1C(=O)N[C@@H]1C(=O)N2CCC[C@@H]2C(=O)NCC(=O)N[C@@H](C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(NCC(=O)N[C@H](C)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCSC)C(=O)NCC(=O)N[C@H](CS[C@@H]2C)C(=O)N[C@H](CC(N)=O)C(=O)N[C@H](CCSC)C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(N[C@H](C)C(=O)N[C@@H]3C(=O)N[C@@H](C(N[C@H](CC=4NC=NC=4)C(=O)N[C@H](CS[C@@H]3C)C(=O)N[C@H](CO)C(=O)N[C@H]([C@H](C)CC)C(=O)N[C@H](CC=3NC=NC=3)C(=O)N[C@H](C(C)C)C(=O)NC(=C)C(=O)N[C@H](CCCCN)C(O)=O)=O)CS[C@@H]2C)=O)=O)CS[C@@H]1C NVNLLIYOARQCIX-MSHCCFNRSA-N 0.000 description 1
- 101710160107 Outer membrane protein A Proteins 0.000 description 1
- 102400000319 Oxyntomodulin Human genes 0.000 description 1
- 101800001388 Oxyntomodulin Proteins 0.000 description 1
- 102000018886 Pancreatic Polypeptide Human genes 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 108090000445 Parathyroid hormone Proteins 0.000 description 1
- 102100025757 Paternally-expressed gene 3 protein Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 102100040918 Pro-glucagon Human genes 0.000 description 1
- NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical group CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101800004937 Protein C Proteins 0.000 description 1
- 102000017975 Protein C Human genes 0.000 description 1
- 102000003743 Relaxin Human genes 0.000 description 1
- 108090000103 Relaxin Proteins 0.000 description 1
- 101800001700 Saposin-D Proteins 0.000 description 1
- 108010086019 Secretin Proteins 0.000 description 1
- 102100037505 Secretin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 102100022831 Somatoliberin Human genes 0.000 description 1
- 101710142969 Somatoliberin Proteins 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 101000983124 Sus scrofa Pancreatic prohormone precursor Proteins 0.000 description 1
- 102000000479 TCF Transcription Factors Human genes 0.000 description 1
- 108010016283 TCF Transcription Factors Proteins 0.000 description 1
- 102000003790 Thrombin receptors Human genes 0.000 description 1
- 102000012607 Thrombomodulin Human genes 0.000 description 1
- 108010079274 Thrombomodulin Proteins 0.000 description 1
- 102000011923 Thyrotropin Human genes 0.000 description 1
- 108010061174 Thyrotropin Proteins 0.000 description 1
- 102100030951 Tissue factor pathway inhibitor Human genes 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 description 1
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 description 1
- 229940024142 alpha 1-antitrypsin Drugs 0.000 description 1
- 229910000148 ammonium phosphate Inorganic materials 0.000 description 1
- 235000019289 ammonium phosphates Nutrition 0.000 description 1
- 108010072788 angiogenin Proteins 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 1
- 150000007860 aryl ester derivatives Chemical class 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 229960000182 blood factors Drugs 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- RSOCSVWZTHPBBQ-UHFFFAOYSA-N carbonic acid;pyrrolidine-2,5-dione Chemical compound OC(O)=O.O=C1CCC(=O)N1 RSOCSVWZTHPBBQ-UHFFFAOYSA-N 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940107137 cholecystokinin Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 239000002442 collagenase inhibitor Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 102000026898 cytokine binding proteins Human genes 0.000 description 1
- 108091008470 cytokine binding proteins Proteins 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- AFOSIXZFDONLBT-UHFFFAOYSA-N divinyl sulfone Chemical class C=CS(=O)(=O)C=C AFOSIXZFDONLBT-UHFFFAOYSA-N 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000010437 erythropoiesis Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229960004222 factor ix Drugs 0.000 description 1
- 229940012414 factor viia Drugs 0.000 description 1
- 229960000301 factor viii Drugs 0.000 description 1
- 229940012444 factor xiii Drugs 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 102000034240 fibrous proteins Human genes 0.000 description 1
- 108091005899 fibrous proteins Proteins 0.000 description 1
- 210000003495 flagella Anatomy 0.000 description 1
- 229940028334 follicle stimulating hormone Drugs 0.000 description 1
- 108010077689 gamma-aminobutyryl-2-methyltryptophyl-2-methyltryptophyl-2-methyltryptophyl-lysinamide Proteins 0.000 description 1
- PUBCCFNQJQKCNC-XKNFJVFFSA-N gastrin-releasingpeptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)C(C)C)[C@@H](C)O)C(C)C)[C@@H](C)O)C(C)C)C1=CNC=N1 PUBCCFNQJQKCNC-XKNFJVFFSA-N 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 102000034238 globular proteins Human genes 0.000 description 1
- 108091005896 globular proteins Proteins 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 229940006607 hirudin Drugs 0.000 description 1
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000002637 immunotoxin Effects 0.000 description 1
- 229940051026 immunotoxin Drugs 0.000 description 1
- 239000002596 immunotoxin Substances 0.000 description 1
- 231100000608 immunotoxin Toxicity 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 102000002467 interleukin receptors Human genes 0.000 description 1
- 108010093036 interleukin receptors Proteins 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 108010013555 lipoprotein-associated coagulation inhibitor Proteins 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229920001427 mPEG Polymers 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- PXZWGQLGAKCNKD-DPNMSELWSA-N molport-023-276-326 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 PXZWGQLGAKCNKD-DPNMSELWSA-N 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 229940053128 nerve growth factor Drugs 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000004309 nisin Substances 0.000 description 1
- 235000010297 nisin Nutrition 0.000 description 1
- 230000002188 osteogenic effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 210000004896 polypeptide structure Anatomy 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical class [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229960000856 protein c Drugs 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 230000013878 renal filtration Effects 0.000 description 1
- 239000002461 renin inhibitor Substances 0.000 description 1
- 229940086526 renin-inhibitors Drugs 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 229960002101 secretin Drugs 0.000 description 1
- OWMZNFCDEHGFEP-NFBCVYDUSA-N secretin human Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(N)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 OWMZNFCDEHGFEP-NFBCVYDUSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 229960005202 streptokinase Drugs 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 108010093640 thrombin receptor peptide SFLLRNP Proteins 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 235000021241 α-lactalbumin Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G81/00—Macromolecular compounds obtained by interreacting polymers in the absence of monomers, e.g. block polymers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
- C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
- C12N11/08—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01017—Lysozyme (3.2.1.17)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Polymers & Plastics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明公开了一种活性多肽或蛋白的聚乙二醇缀合物的制备方法,其包括将活性多肽或蛋白与聚乙二醇混合反应的步骤,其中,所述聚乙二醇含有单活性官能团且未事先与非聚乙二醇原功能结构连接,在所述反应的反应液中,共轭酸碱对的总浓度为0.13‑5.5M。一般来说,PEG化修饰会使活性分子的活性不同程度的下降,修饰度越高活性下降幅度越大。但在本发明中,通过增加离子强度提高修饰度,多肽或蛋白的活性并未因修饰度的提高而显著降低。
Description
技术领域
本发明涉及生物技术领域,具体涉及一种活性多肽或蛋白的聚乙二醇缀合物的制备方法。
背景技术
活性多肽及蛋白因其独特的生物学效应,被广泛用于各类疾病的治疗,但这类药物容易被血液中的蛋白酶水解并通过肾脏或肝脏被排除。为了维持多肽或蛋白药物在血液中的有效浓度,往往需要频繁地向患者注射药物,这给患者带来了很大的痛苦,并且会产生高昂的治疗费用。此外,外源多肽及蛋白所引起的免疫原性同样是用药时需要考虑的安全问题。
聚乙二醇化是一种常用的提高活性成分成药性的方法,具有提高活性成分的水溶性、减少免疫原性、降低肾脏滤过作用、延长体内循环半衰期、改变组织分布等效果。该技术一般通过化学反应或酶促反应将聚乙二醇(PEG)分子共价连接到活性分子上。在此之前,通常需要对PEG进行适当的化学改造,引入特定的官能团,以适应之后的对活性分子的共价修饰过程。
在PEG化技术中,高质量的PEG原料制备工艺较复杂,生产成本较高。因此,在偶联反应中提高反应转化率对减少物料损耗和降低生产成本具有十分重要的意义。
发明内容
本发明所要解决的技术问题是现有技术中用聚乙二醇修饰多肽或蛋白时的反应转化率不高的问题,从而提供了一种活性多肽或蛋白的聚乙二醇缀合物的制备方法。
本发明解决上述技术问题的技术方案为:一种活性多肽或蛋白聚乙二醇缀合物的制备方法,其包括将活性多肽或蛋白与聚乙二醇混合反应的步骤,其中,所述聚乙二醇含有单活性官能团且未事先与非聚乙二醇原功能结构连接,在所述反应的反应液中,共轭酸碱对的总浓度为0.13-5.5M。
所述聚乙二醇原功能结构包括:活性官能团、乙二醇重复单元和封端基团,其余均为“非聚乙二醇原功能结构”,所述非聚乙二醇原功能结构优选多肽或蛋白。
本发明所述“聚乙二醇”具有本领域普通技术人员通常理解的含义,其可以为线性的、分枝的、分叉的或由多个臂组成,不同的聚乙二醇可以具有不同的聚合链长度和聚合结构。
“聚乙二醇原功能结构”主要包括(CH2CH2O)n重复单元,还可以包括活性官能团和封端基团。活性官能团具有高反应活性,用于和活性多肽或蛋白进行缀合,可选的活性官能团包括卤素、乙烯基砜、二硫键、巯基、醛基、羰基、O-取代羟氨、活性酯、烯基、炔基、叠氮基或其他活化基团,具体来说,包括但不限于丙醛基、丁醛基等醛衍生物、马来酰亚胺衍生物、琥珀酰亚胺衍生物及芳基酯类衍生物等。所述琥珀酰亚胺衍生物可使用琥珀酰亚胺羧基甲酯、琥珀酰亚胺戊酸酯、琥珀酰亚胺丁酸甲酯、琥珀酰亚胺丙酸甲酯、琥珀酰亚胺丁酸酯、琥珀酰亚胺丙酸酯、羟基琥珀酰亚胺或琥珀酰亚胺碳酸酯;在一些实施方案中,所述活性官能团可以为活性酯,包括琥珀酰亚胺丙酸酯(SPA)、琥珀酰亚胺碳酸酯(SC)、硝基苯基碳酸酯(NPC)等。封端基团可以为羟基,也可以为其他基团,包括但不限于烷氧基、环烷氧基、环烷基氧基、烯基、芳基氧基或芳烷基氧基等,在一些实施方案中,所述封端基团为烷氧基,优选为甲氧基。
除前述(CH2CH2O)n重复单元、活性官能团和封端基团外,其他与聚乙二醇所发挥生物学效应无关的结构为“非聚乙二醇原功能结构”,所述非聚乙二醇原功能结构优选多肽或蛋白。
本发明所述“多肽”指由3个或3个以上氨基酸分子脱水缩合形成的线性氨基酸链,分子量通常低于10,000Da,其中生物体中具有某种生理功能的多肽称为活性多肽,拥有多肽结构的共同点,且具有各种生理活性。所述活性多肽发挥调整基因表达及生理功能,当因在体内参与功能调节的物质缺乏或过度分泌而呈现不正常的病态时进行纠正的作用,可包含通常的蛋白治疗剂。活性多肽包括免疫活性肽、神经活性肽、其他活性肽等。其他活性肽包括:胆固醇肽、促进矿物质吸收的肽(CPPS)、酶调节剂(如促胰酶肽)、激素肽如生长激素释放因子(GRFS)、白蛋白胰岛素增效肽、抗菌多肽(如乳酸链球菌素、橡胶素)、抗癌多肽(如肿瘤细胞坏死因子、环已肽)、抗艾滋病肽(如GLQ蛋白)等。
本发明所述“蛋白质”指由氨基酸以脱水缩合的方式组成的多肽链经过盘曲折叠形成的具有一定空间结构(包括二级结构、三级结构或四级结构)的物质。蛋白质可以只具有一条多肽链,也可以是由多条多肽链构成,具有通常都具有生物学活性。根据蛋白质分子的外形,可以将其分作3类:1.球状蛋白质;分子形状接近球形,水溶性较好,可行使多种多样的生物学功能。2.纤维状蛋白质分子;外形呈棒状或纤维状,大多数不溶于水,是生物体重要的结构成分,或对生物体起保护作用。3.膜蛋白质;一般折叠成近球形,插入生物膜,也有一些通过非共价键或共价键结合在生物膜的表面。生物膜的多数功能是通过膜蛋白实现的。
蛋白质在生物体中有多种功能,例如催化功能、运动功能、运输功能、机械支持和保护功能、免疫和防御功能和调节功能等。有催化功能的蛋白质称酶。从最低等的细菌鞭毛运动到高等动物的肌肉收缩都是通过蛋白质实现的。在生命活动过程中,许多小分子及离子的运输是由各种专一的蛋白质来完成的,例如在血液中血浆白蛋白运送小分子、红细胞中的血红蛋白运送氧气和二氧化碳等。生物体为了维持自身的生存,拥有多种类型的防御手段,其中不少是靠蛋白质来执行的,例如抗体能识别和结合侵入生物体的外来物质,消除其有害作用。
所述单活性官能团指的是所述聚乙二醇仅含有一个活性官能团,所述活性官能团为本领域常规,例如醛衍生物、马来酰亚胺衍生物和琥珀酰亚胺衍生物等。
在本发明的一些优选实施方案中,所述共轭酸碱对的总浓度为0.2M、0.3M、0.4M、0.5M、0.6M、0.7M、0.8M、0.9M、1.0M、1.1M、1.2M、1.3M、1.4M、1.5M、1.6M、1.7M、1.8M、1.9M、2.0M、2.2M、2.3M、2.4M、2.5M、2.6M、2.7M、2.8M、2.9M、3.0M、3.1M、3.2M、3.3M、3.4M、3.5M、3.6M、3.7M、3.8M、3.9M、4.0M、4.1M、4.2M、4.3M、4.4M、4.5M、4.6M、4.7M、4.8M、4.9M、5.0M、5.1M、5.2M、5.3M、5.4M、5.5M。
如本发明技术方案所述的制备方法,所述共轭酸碱对的总浓度为0.15-3M,优选为0.2-2.5M。
如本发明技术方案所述的制备方法,所述共轭酸碱对包括缓冲溶液,或缓冲溶液和额外添加的盐。
所述缓冲溶液为本领域常规,在本发明的较佳实施方案中,所述缓冲溶液选自硼酸缓冲液、磷酸缓冲液、碳酸缓冲液、醋酸缓冲液、枸橼酸缓冲液、PBS、Tris和HEPES中的一种或多种。
在本发明的更佳实施方案中,所述缓冲溶液选自硼酸缓冲液、磷酸缓冲液和碳酸缓冲液中的一种或多种。
在本发明的进一步更佳实施方案中,所述缓冲溶液为磷酸缓冲液。
如本发明技术方案所述的制备方法,所述共轭酸碱对包括缓冲溶液,所述缓冲溶液的浓度为0.15-3M。
在本发明的一些优选实施方案中,所述缓冲液的浓度为0.2M、0.3M、0.4M、0.5M、0.6M、0.7M、0.8M、0.9M、1.0M、1.1M、1.2M、1.3M、1.4M、1.5M、1.6M、1.7M、1.8M、1.9M、2.0M。
在本发明的具体实施方案中,所述缓冲液的浓度优选为0.2-2M;更优选为0.25-1M;例如为0.3-0.8M。
如本发明技术方案所述的制备方法,所述共轭酸碱对包括缓冲溶液和额外添加的盐,所述缓冲溶液的浓度为0.02-0.3M,优选为0.03-0.2M,更优选为0.05-0.15M。
本发明所额外添加的盐可为本领域常规,例如所述盐可选自由氯化钠(sodiumchloride)、乙酸钠(sodium acetate)、硫酸钠(sodium sulfate)、磷酸钠(sodiumphosphate)、碳酸钠(sodium carbonate)、氰化钠(sodium cyanide)、柠檬酸钠(sodiumcitrate)、硝酸钠(sodium nitrate)、氯化钾(potassium chloride)、乙酸钾(potassiumacetate)、硫酸钾(potassium sulfate)、磷酸钾(potassium phosphate)、碳酸钾(potassium carbonate)、氰化钾(potassium cyanide)、柠檬酸钾(potassium citrate)、硝酸钾(potassium nitrate)、氯化镁(magnesium chloride)、乙酸镁(magnesiumacetate)、硫酸镁(magnesium sulfate)、磷酸镁(magnesium phosphate)、碳酸镁(magnesium carbonate)、氰化镁(magnesium cyanide)、柠檬酸镁(magnesium citrate)、硝酸镁(magnesium nitrate)、氯化铵(ammonium chloride)、乙酸铵(ammonium acetate)、硫酸铵(ammonium sulfate)、磷酸铵(ammonium phosphate)、碳酸铵(ammoniumcarbonate)、氰化铵(ammonium cyanide)、柠檬酸铵(ammonium citrate)、硝酸铵(ammonium nitrate)、氯化钙(calcium chloride)、乙酸钙(calcium acetate)、硫酸钙(calcium sulfate)、磷酸钙(calcium phosphate)、碳酸钙(calcium carbonate)、氰化钙(calcium cyanide)、柠檬酸钙(calcium citrate)或硝酸钙(calcium nitrate)所构成的群组,但并不限制于此。
如本发明技术方案所述的制备方法,所述额外添加的盐选自NaCl、KCl、NH4Cl、MgCl2、CaCl2、Na2CO3、NaHCO3、CH3COONa、NaH2PO4、Na2HPO4、KH2PO4、K2HPO4、Na2SO4、K2SO4、(NH4)2SO4、MgSO4和CaSO4中的一种或多种。
在本发明的较佳实施方案中,所述额外添加的盐选自NaCl、KCl、NH4Cl、K2HPO4、CH3COONa、Na2SO4、K2SO4、(NH4)2SO4中的一种或多种。
如本发明技术方案所述的制备方法,所述额外添加的盐的浓度为0.02-5M。
在本发明的一些优选实施方案中,所述额外添加的盐的浓度为0.2M、0.3M、0.4M、0.5M、0.6M、0.7M、0.8M、0.9M、1.0M、1.1M、1.2M、1.3M、1.4M、1.5M、1.6M、1.7M、1.8M、1.9M、2.0M、2.2M、2.3M、2.4M、2.5M、2.6M、2.7M、2.8M、2.9M、3.0M、3.1M、3.2M、3.3M、3.4M、3.5M、3.6M、3.7M、3.8M、3.9M、4.0M、4.1M、4.2M、4.3M、4.4M、4.5M、4.6M、4.7M、4.8M、4.9M、5.0M。
在本发明的具体实施方案中,所述额外添加的盐的浓度优选为0.05-4M;更优选为0.1-3M,例如优选为0.5-2M。
如本发明技术方案所述的制备方法,所述额外添加的盐为Na2SO4,浓度为0.02-1M,优选为0.1-0.8M,更优选为0.2-0.5M。
如本发明技术方案所述的制备方法,所述额外添加的盐为NaCl,浓度为0.05-5.0M,优选为0.1-4.0M,更优选为0.2-3M,甚至更优选为0.5-2M。
如本发明技术方案所述的制备方法,所述额外添加的盐为CH3COONa,浓度为0.5-2.5M,优选为0.9-1.8M,优选1.8M;或,所述额外添加的盐为KCl,浓度为0.2-2.0M,优选为0.7-1.6M,优选1.6M;或,所述额外添加的盐为K2HPO4,浓度为0.05-1.0M,优选为0.1-0.5M,优选0.45M。
如本发明技术方案所述的制备方法,所述活性多肽或蛋白可选自由尿酸酶、溶菌酶、人生长激素、生长激素释放激素、生长激素释放肽、干扰素、干扰素受体、集落刺激因子、类胰高血糖素肽(GLP-1等)、胃泌酸调节素、G蛋白偶联受体(Gprotein-coupledreceptor)、白细胞介素、白细胞介素受体、酶类、白细胞介素结合蛋白、细胞因子结合蛋白、巨噬细胞活化因子、巨噬细胞肽、B细胞因子、T细胞因子、蛋白质A、变态反应抑制因子、细胞坏死糖蛋白、免疫毒素、淋巴毒素、肿瘤坏死因子、肿瘤抑制因子、转化生长因子、α-1抗胰蛋白酶、白蛋白、α-乳白蛋白、载脂蛋白E、促红细胞生成因子、高糖基化促红细胞生成因子、血管生成素、血红素、凝血酶、凝血酶受体活化肽、血栓调节素、血液因子VII、VIIa、VIII、IX与XIII、纤溶酶原活性因子、纤维蛋白肽、尿激酶、链球菌激酶、水蛭素、蛋白质C、C-反应蛋白、肾素抑制剂、胶原酶抑制剂、超氧化岐化酶、瘦蛋白、血小板衍生生长因子、上皮细胞生长因子、表皮细胞生长因子、血管抑制素、血管收缩素、骨生长因子、促骨生成蛋白、降血钙素、胰岛素、心钠素、软骨诱导因子、依降钙素、结缔组织活化因子、组织因子途径抑制剂、卵泡刺激素、黄体生成素、黄体生成素释放激素、神经生长因子、甲状旁腺激素、松弛素、分泌素、生长调节素、类胰岛素生长因子、肾上腺皮质激素、胰高血糖素、胆囊收缩素、胰腺多肽、促胃泌素释放肽、促肾上腺皮质激素释放因子、促甲状腺刺激激素、自毒素、乳铁蛋白、肌肉抑制素、细胞表面抗原、来自病毒的疫苗抗原、单克隆抗体、多克隆抗体及抗体片段所构成的群组,但并不限制于此。
在本发明的具体实施方案中,所述活性多肽或蛋白为酶,例如尿酸酶或溶菌酶。
本发明中的尿酸酶可来源于人、哺乳动物、植物、微生物或人与哺乳动物尿酸酶的杂合体,优选来源于微生物,更优选来源于真菌和细菌,例如球形节杆菌、黄曲霉、产朊假丝酵母、苛求芽孢杆菌等。
在本发明的具体实施方案中,所述尿酸酶来源于球形节杆菌Arthrobacterglobiformis,所述尿酸酶的氨基酸序列优选如SEQ ID NO:1所示,或所述尿酸酶的氨基酸序列与SEQ ID NO:1相比具有至少90%、至少95%或者至少99%的序列同一性,同时至少保留原本序列的功能。
如本发明技术方案所述的制备方法,反应液中所述活性多肽或蛋白的浓度为0.5-2.5mg/mL,例如为1.0-2.0mg/mL。
在本发明的优选实施方案中,所述活性多肽或蛋白为尿酸酶,浓度为1.5-2.5mg/mL,例如2.0mg/mL。或所述活性多肽或蛋白为溶菌酶,浓度为0.5-1.5mg/mL,例如1.0mg/mL。
如本发明技术方案所述的制备方法,所述聚乙二醇的分子量为1kDa-50kDa,优选为5kDa-30kDa。例如所述聚乙二醇的分子量为5kDa、10kDa、20kDa、30kDa或50kDa。
在本发明的较佳实施方案中,所述聚乙二醇的封端为甲氧基;和/或,所述聚乙二醇的活性官能团为醛衍生物、马来酰亚胺衍生物或琥珀酰亚胺衍生物,优选为N琥珀酰亚胺丙酸酯、琥珀酰亚胺碳酸酯或硝基苯基碳酸酯。
在本发明的更佳实施方案中,所述聚乙二醇为mPEG-SPA-5K、mPEG-SPA-10K、mPEG-SC-5K和/或mPEG-NPC-10K。
如本发明技术方案所述的制备方法,反应液中所述聚乙二醇和所述活性多肽或蛋白的质量比为2:1~50:1,优选为3:1~30:1,更优选为5:1~25:1。
如本发明技术方案所述的制备方法,所述反应的温度为5~30℃,优选为20~25℃,更优选为25℃。
如本发明技术方案所述的制备方法,所述反应的pH值为6.0~10.0,优选为6.5~9.5,更优选为7.0~9.0,甚至更优选为7.5~8.7,更优选为8.7。
如本发明技术方案所述的制备方法,所述聚乙二醇的活性官能团可与所述活性多肽或蛋白的N末端氨基、Lys侧链氨基、His侧链咪唑基以及Ser或Tyr侧链羟基反应,但并不限制于此。
在本发明中,对于聚乙二醇定点修饰的多肽或蛋白,转化率指反应底物的转化率;对于聚乙二醇随机修饰的多肽或蛋白,转化率指平均修饰度。
在符合本领域常识的基础上,上述各优选条件,可任意组合,即得本发明各较佳实例。
本发明所用试剂和原料均市售可得。
本发明的积极进步效果在于:
本发明人发现在活性多肽或蛋白与聚乙二醇缀合的反应中,增加反应液离子强度即可以提高反应转化率。
反应转化率的提高程度具有离子强度依赖性,随着反应液离子强度的逐步提高,反应转化率逐步提高。多种类型的盐的添加都能提高修饰度,且盐浓度越大,修饰度提高的幅度越大。
一般来说,PEG化修饰会使活性分子的活性不同程度的下降,修饰度越高活性下降幅度越大。但在本发明中,通过增加离子强度提高修饰度,多肽或蛋白的活性并未因修饰度的提高而显著降低。
附图说明
图1为反应编号3-1~3-4的样品SDS-PAGE结果图。
图2为反应编号5-1~5-18的样品SDS-PAGE结果图。
图3为反应编号5-19~5-30的样品SDS-PAGE结果图。
图4为不同投料比的系列反应中盐浓度和平均修饰度的相关性曲线图。
图5为酶比活和平均修饰度与盐浓度之间相关性的曲线图。
图6为平均修饰度的实验值和方程预测值的对比。
图7为反应编号9-1~9-6的样品SDS-PAGE结果图。
具体实施方式
术语解释:
本发明中,“修饰度”指的是被修饰分子上偶联的缀合物分子的数量。“平均修饰度”指的是对于由一群具有不同修饰度的分子形成的混合物,将缀合物分子的物质的量除以被修饰分子的物质的量,得到的比值。
本发明中的“盐”是指一类金属离子或铵根离子(NH4+)与酸根离子结合的化合物,不是狭义的氯化钠,可溶盐的溶液及熔盐有导电性,因此可作为电解质。
本发明中,聚乙二醇(PEG)泛指各种聚乙二醇和其衍生物,非特指H-(OCH2CH2)n-OH,而是以“-(OCH2CH2)n-”为主要结构的一类化合物。
本发明中,mPEG-SC(mPEG-Succinimidyl Carbonate,单甲氧基聚乙二醇琥珀酰亚胺碳酸酯)为羟基末端活化为琥珀酰亚胺碳酸酯的单甲氧基聚乙二醇(mPEG)修饰剂。
本发明中,mPEG-SPA(mPEG-Succinimidyl Propionnate,单甲氧基聚乙二醇琥珀酰亚胺丙酸酯)为羟基末端活化为琥珀酰亚胺丙酸酯的单甲氧基聚乙二醇(mPEG)修饰剂。
mPEG-NPC(mPEG-Nitrophenyl Carbonate,甲氧基-聚乙二醇-硝基苯基碳酸酯)为一种线本发明中性单官能团甲基醚PEG,带有活性硝基苯碳酸酯或NPC基团。
本发明中,“反应转化率”包含两层含义:反应物转化为产物的程度和比例;或者被修饰分子的修饰度。反应转化率高,则反应物转化成产物的比例大;或者修饰度高。
本发明中,“离子强度”指的是以离子的体积摩尔浓度计算所得的离子强度,单位mol/L。
本发明中,尿酸酶为球形节杆菌(Arthrobacter globiformis)的尿酸酶(UniProtKB-D0VWQ1),其氨基酸序列如SEQ ID NO:1所示:
MTATAETSTGTKVVLGQNQYGKAEVRLVKVTRNTARHEIQDLNVTSQLRGDFEAAHTAGDNAHVVATDTQKNTVYAFARDGFATTEEFLLRLGKHFTEGFDWVTGGRWAAQQFFWDRINDHDHAFSRNKSEVRTAVLEISGSEQAIVAGIEGLTVLKSTGSEFHGFPRDKYTTLQETTDRILATDVSARWRYNTVEVDFDAVYASVRGLLLKAFAETHSLALQQTMYEMGRAVIETHPEIDEIKMSLPNKHHFLVDLQPFGQDNPNEVFYAADRPYGLIEATIQREGSRADHPIWSNIAGFC,其中,BL21(DE3)菌株表达时第一位氨基酸M会被切除。
本发明中,溶菌酶为鸡蛋溶菌酶,Lysozyme,采购自SIGMA-ALDRICH,货号62971-10G-F,CAS:12650-88-3。
本发明中,N02指的是多肽,序列Ac-LGGSKGGSWG(SEQ ID NO:2),Ac代表N末端乙酰化。
本发明中,Tris为三羟甲基氨基甲烷,CAS:77-86-1;EDTA为乙二胺四乙酸,CAS:60-00-4;UA为尿酸,CAS:69-93-2;DMSO为二甲亚砜,CAS:67-68-5。
查化学手册获得各种盐的溶解度信息,见下表1。
表1
下面通过实施例的方式进一步说明本发明,但并不因此将本发明限制在所述的实施例范围之中。下列实施例中未注明具体条件的实验方法,按照常规方法和条件,或按照商品说明书选择。
实施例1尿酸酶对盐浓度的耐受性
尿酸酶通过大肠杆菌发酵表达后经提纯所得,浓度通过UV280nm吸光度法测定。4.0mg/mL尿酸酶在200mM pH 8.7硼酸缓冲溶液中。
按下表2混合各溶液,测试尿酸酶对盐浓度的耐受情况,目测是否形成不溶性物质。测试显示尿酸酶对多种类型的盐在相当高的浓度下都保持稳定。
表2
实施例2mPEG-SPA(5kDa)修饰尿酸酶
2.0mg/mL尿酸酶在100mM pH8.7硼酸缓冲溶液中,此外溶液中额外含有如下表3所示的盐。取蛋白溶液0.5mL,加入10mg mPEG-SPA(5kDa,采购自日本油脂),25℃反应2h。
表3
反应完毕后SDS-PAGE变性电泳,考马斯亮蓝染色分析反应结果,如图1,M是蛋白分子量标准品,U是尿酸酶,3-1~3-4代表反应编号3-1~3-4。结果显示随着盐浓度的逐步提高,平均修饰度不断提高。电泳图使用FIJI软件分析,获得修饰产物各成分百分比的定量数据,如表4所示。PEG0、PEG1、PEG2、PEG3、PEG4、PEG5代表不同的修饰度的产物,其中PEG代表聚乙二醇分子,数字代表修饰度。PEG0代表未被修饰的尿酸酶。平均修饰度的计算公式如下:
M:平均修饰度;
i:修饰度;
PEGi%:修饰度为i的成分的百分比。
表4
实施例3从实施例2中获得的样品的酶活测定
酶活测定条件:
缓冲液(BF8):50mM pH8.0 Tris-HCl缓冲溶液,另含2.0mM EDTA二钠;
尿酸溶液(UA100):100μM,使用BF8溶解;
测试温度:约25℃;
实施例2中获得的各样品,使用BF8稀释到合适浓度。取50μL样品稀释液,加入950μL UA100,迅速混匀后测定UV290nm的光吸收,记录最初的120s吸收值的下降幅度。测试结果如下表5。
数据显示各修饰产物活性保留程度很高(70-90%)。一般来说,PEG化修饰会使活性分子的活性不同程度的下降,修饰度越高活性下降幅度越大。但有趣的是反应3-2~3-4的修饰度虽然显著高于反应3-1,但活性保留比例并未显著低于反应3-1,甚至还不同程度的有所提高。
表5
实施例4mPEG-SPA(10kDa)修饰尿酸酶
2.0mg/mL尿酸酶在100mM pH8.7硼酸缓冲溶液中,此外溶液中额外含有如下表6所示的盐。取蛋白溶液适量,加入计算量的mPEG-SPA(10kDa,采购自北京键凯),25℃反应2h。
表6
反应完毕后,按照实施例2的方式进行分析处理。电泳结果如图2、图3所示,M是蛋白分子量标准品,数字代表反应编号。各反应的产物组成百分比和平均修饰度见下表7和图4。结果显示,在各种不同投料比的系列反应中,伴随盐浓度的提高,修饰度都呈现趋势性上升。
表7
实施例5从实施例4中获得的样品的酶活测定
酶活测定条件:
缓冲液(BF8):50mM pH8.0 Tris-HCl缓冲溶液,另含2.0mM EDTA二钠;尿酸溶液(UA100):100μM,使用BF8溶解;
测试温度:约25℃;
实施例4中获得的各样品,使用BF8稀释到合适浓度。取100μL样品稀释液,加入900μL UA100,迅速混匀后测定UV290nm的光吸收,记录光吸收时间曲线,根据曲线计算酶比活。10倍投料比的结果如下表8和图5。与实施例3的结果类似,盐浓度的上升提高了平均修饰度,但产物活性并未因此发生显著降低。
表8
实施例6修饰度方程
根据上述实施例4的实验数据,进行二元二次方程拟合,获得如下方程(R2=0.9831);并根据方程比较平均修饰度的方程计算值和实验值的差异,如下表9和图6所示。
M=-0.001273×N2-0.3372×C2+0.01936×N×C+0.1351×N+0.9055×C+0.4218
R2:0.9831
M:平均修饰度,≥0;
N:投料比,PEG/尿酸酶(m/m),≥0;
C:氯化钠浓度,单位mol/L,≥0.
表9
实施例7改变盐的类型
2.0mg/mL尿酸酶在100mM pH8.7硼酸缓冲溶液中,此外溶液中额外含有如下表10所示的盐。取蛋白溶液0.25mL,加入7.5mg的mPEG-SPA(10kDa,采购自北京键凯),25℃反应2h。反应转化率的提高程度具有离子强度依赖性;随着反应液离子强度的提高,反应转化率提高。多种类型的盐的添加都能提高修饰度,且盐浓度越大,修饰度提高的幅度越大。
表10
实施例8改变修饰反应浓度
1.0mg/mL尿酸酶在100mM pH8.7硼酸缓冲溶液中,此外溶液中额外含有如下表11所示的盐。取尿酸酶0.5mL,加入10mg mPEG-SPA(10kDa,采购自北京键凯),25℃反应2h。
表11
反应完毕后,按照实施例2的方式进行分析处理。电泳结果如图7,数字代表反应编号。试验结果同实施例2和4保持一致,随着盐浓度的提高,修饰度上升。
实施例9改变pH值
2.0mg/mL尿酸酶在不同浓度的pH7.5的磷酸钾缓冲溶液中。取各尿酸酶0.5mL,加入15mg mPEG-SPA(10kDa,采购自北京键凯),25℃反应2h。反应完毕后,按照实施例2的方式进行分析处理。结果显示,随着磷酸钾缓冲盐浓度升高,平均修饰度提高,如下表12。本实施例说明:①增加离子强度提高反应转化率的效果在不同的pH值条件下都起效;②仅通过提高缓冲溶液的浓度来提高反应液的离子强度,也能达到增加反应转化率的效果。
表12
实施例10mPEG-SC(5kDa)和mPEG-NPC(10kDa)修饰尿酸酶
2.0mg/mL尿酸酶在50mM pH8.7硼酸缓冲溶液中,此外溶液中额外含有如下表13所示的盐。按表中配比进行反应,25℃反应2h。反应完毕后,按照实施例2的方式进行分析处理。结果显示,无论是mPEG-SC-5K(5kDa,采购自日本油脂),还是mPEG-NPC-10K(10kDa,采购自日本油脂),平均修饰度都随着盐浓度的提高而提高。
表13
实施例11不同温度下聚乙二醇修饰Lys侧链氨基
N02(氨基酸序列为SEQ ID NO:2的多肽)用DMSO配置成5mg/mL的浓液,并用pH9.5100mM碳酸钠缓冲液稀释到1mg/mL,此外在溶液中还额外添加如下表14所示的盐。取0.5mLN02溶液,加入5mg mPEG-SC(20kDa,采购自北京键凯),按表14所示条件反应2h。反应完毕后,使用RP-HPLC分析反应转化率,色谱柱:C18-300A-4.6*250mm(Phenomenex);流动相A:0.05% TFA in H2O;流动相B:0.05% TFA in CAN;柱温:25℃;流速:1mL/min。如表14,无论在5℃条件下反应,还是在室温(约25℃)条件下反应,在反应液中添加盐都有利于提高反应转化率。
表14
实施例12聚乙二醇化溶菌酶
1.0mg/mL溶菌酶在50mM pH8.5硼酸缓冲溶液中,此外溶液中额外含有如下表15所示的盐。取酶溶液5mL,加入20mg PEG室温反应,见下表15。反应结束后使用实施例2的方法分析平均修饰度。结果显示硫酸钠浓度的增大提高了平均修饰度。
表15
Claims (10)
1.一种活性多肽或蛋白的聚乙二醇缀合物的制备方法,其包括将活性多肽或蛋白与聚乙二醇混合反应的步骤,其特征在于,所述聚乙二醇含有单活性官能团且未事先与非聚乙二醇原功能结构连接,在所述反应的反应液中,共轭酸碱对的总浓度为0.13-5.5M。
2.如权利要求1所述的制备方法,其特征在于,所述共轭酸碱对的总浓度为0.15-3M,优选为0.2-2.5M。
3.如权利要求1或2所述的制备方法,其特征在于,所述共轭酸碱对包括缓冲溶液,或缓冲溶液和额外添加的盐;
较佳地,所述缓冲溶液选自硼酸缓冲液、磷酸缓冲液、碳酸缓冲液、醋酸缓冲液、枸橼酸缓冲液、PBS、Tris和HEPES中的一种或多种;
更佳地,所述缓冲溶液选自硼酸缓冲液、磷酸缓冲液和碳酸缓冲液中的一种或多种。
4.如权利要求3所述的制备方法,其特征在于,所述共轭酸碱对包括缓冲溶液,所述缓冲溶液的浓度为0.15-3M;优选为0.2-2M;更优选为0.25-1M;甚至更优选为0.3-0.8M。
5.如权利要求3所述的制备方法,其特征在于,所述共轭酸碱对包括缓冲溶液和额外添加的盐,所述额外添加的盐选自NaCl、KCl、NH4Cl、MgCl2、CaCl2、Na2CO3、NaHCO3、CH3COONa、NaH2PO4、Na2HPO4、KH2PO4、K2HPO4、Na2SO4、K2SO4、(NH4)2SO4、MgSO4和CaSO4中的一种或多种;
较佳地,所述额外添加的盐选自NaCl、KCl、NH4Cl、K2HPO4、CH3COONa、Na2SO4、K2SO4、(NH4)2SO4中的一种或多种;和/或,所述缓冲溶液的浓度为0.02-0.3M,优选为0.03-0.2M,更优选为0.05-0.15M。
6.如权利要求5所述的制备方法,其特征在于,所述额外添加的盐的浓度为0.02-5M;优选为0.05-4M;更优选为0.1-3M,甚至更优选为0.5-2M;较佳地:
所述额外添加的盐为Na2SO4,浓度为0.02-1M,优选为0.1-0.8M,更优选为0.2-0.5M;或,
所述额外添加的盐为NaCl,浓度为0.05-5.0M,优选为0.1-4.0M,更优选为0.2-3M,甚至更优选为0.5-2M;或,
所述额外添加的盐为CH3COONa,浓度为0.5-2.5M,优选为0.9-1.8M;或,
所述额外添加的盐为KCl,浓度为0.2-2.0M,优选为0.7-1.6M;或,
所述额外添加的盐为K2HPO4,浓度为0.05-1.0M,优选为0.1-0.5M。
7.如权利要求1~6任一项所述的制备方法,其特征在于,所述活性多肽或蛋白为酶,例如尿酸酶或溶菌酶;
较佳地,所述尿酸酶来源于微生物,优选细菌;
更佳地,所述尿酸酶来源于球形节杆菌(Arthrobacter globiformis),所述尿酸酶的氨基酸序列优选如SEQ ID NO:1所示。
8.如权利要求1~7任一项所述的制备方法,其特征在于,反应液中所述活性多肽或蛋白的浓度为0.5-2.5mg/mL。
9.如权利要求1~8任一项所述的制备方法,其特征在于,所述聚乙二醇的分子量为1kDa-50kDa,优选为5kDa-30kDa。
10.如权利要求1~9任一项所述的制备方法,其特征在于,反应液中所述聚乙二醇和所述活性多肽或蛋白的质量比为2:1~50:1,优选为3:1~30:1,更优选为5:1~25:1;和/或,
所述反应的pH值为6.0~10.0,优选为6.5~9.5,更优选为7.0~9.0,甚至更优选为7.5~8.7。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210868682 | 2022-07-22 | ||
CN2022108686822 | 2022-07-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117427180A true CN117427180A (zh) | 2024-01-23 |
Family
ID=89545193
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310902991.1A Pending CN117427180A (zh) | 2022-07-22 | 2023-07-21 | 一种活性多肽或蛋白的聚乙二醇缀合物的制备方法 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN117427180A (zh) |
WO (1) | WO2024017379A1 (zh) |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6913915B2 (en) * | 2001-08-02 | 2005-07-05 | Phoenix Pharmacologics, Inc. | PEG-modified uricase |
CN101928704A (zh) * | 2010-03-04 | 2010-12-29 | 杭州北斗生物技术有限公司 | 黄曲霉尿酸氧化酶的聚乙二醇修饰物及其制备方法 |
CN105820232B (zh) * | 2016-04-08 | 2019-05-17 | 昂德生物药业有限公司 | 单修饰聚乙二醇重组人促红素的制备方法及其制品和应用 |
CN114438047A (zh) * | 2020-11-05 | 2022-05-06 | 重庆派金生物科技有限公司 | 制备聚乙二醇修饰的尿酸氧化酶的方法 |
-
2023
- 2023-07-21 WO PCT/CN2023/108707 patent/WO2024017379A1/zh unknown
- 2023-07-21 CN CN202310902991.1A patent/CN117427180A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2024017379A1 (zh) | 2024-01-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6243456B2 (ja) | ポリサッカライドによるタンパク質のn末端誘導体化 | |
US6037452A (en) | Poly(alkylene oxide)-Factor VIII or Factor IX conjugate | |
Pasut et al. | State of the art in PEGylation: the great versatility achieved after forty years of research | |
US5006333A (en) | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols | |
EP0400472B1 (en) | Process for preparing polyethylene glycol derivatives and modified protein. | |
US5283317A (en) | Intermediates for conjugation of polypeptides with high molecular weight polyalkylene glycols | |
EP0247860B1 (en) | Tumor necrosis factor formulation and its preparation | |
AU2005224078B2 (en) | Methods for increasing protein polyethylene glycol (PEG) conjugation | |
JP3173794B2 (ja) | タンパク質またはポリペプチド類とその製造法および中間化合物 | |
JP5961730B2 (ja) | 修飾されたエリスロポエチン | |
TWI281864B (en) | N-terminally monopegylated human growth hormone conjugates and process for their preparation | |
JP5657011B2 (ja) | カテコールポリエチレングリコール誘導体と蛋白質またはペプチドの接合体、及びこれの製造方法 | |
KR101042965B1 (ko) | 카테콜 폴리에틸렌글리콜 유도체와 단백질 또는 펩타이드의 접합체 및 이의 제조방법 | |
US20060286657A1 (en) | Novel bioconjugation reactions for acylating polyethylene glycol reagents | |
CN117427180A (zh) | 一种活性多肽或蛋白的聚乙二醇缀合物的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication |